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Diagnosis of invasive aspergillosis remains a significant problem. PCR testing may aid diagnosis but is not yet
included in disease-defining criteria due to a lack of standardization of assays and methodologies. This study
investigated the analytical performance and the clinical sensitivity and specificity of the Myconostica MycAssay
Aspergillus PCR (MAP) assay compared to those of a validated in-house Aspergillus PCR (IHP) test when testing
serum specimens. Serum specimens spiked with Aspergillus genomic DNA had a limit of detection equivalent to 5
genomes and a linear dynamic range of 5 to >5  104 genomes for both assays. When testing clinical specimens
(n  170), the MAP assay had a sensitivity of 60 to 70% and a specificity of 90.5 to 100%. The IHP assay had a
sensitivity of 50 to 80% and a specificity of 100%. A commercially available Aspergillus PCR assay provides a
methodology that is standardized and reagents that are quality controlled. This facilitates multicenter evaluation of
the clinical utility of PCR diagnosis. The performance of the MAP assay is comparable to that of the IHP assay and to
those in previously reported studies evaluating commercial tests (galactomannan enzyme-linked immunosorbent assay).
Despite improved awareness, invasive aspergillosis (IA) is
still a significant problem in the hematological population,
where mortality rates are exacerbated by delayed diagnosis.
Nonculture diagnostic techniques (PCR, galactomannan en-
zyme-linked immunosorbent assay [GM-ELISA], and high-res-
olution computer tomography) may improve the time to diag-
nosis and, consequently, reduce mortality rates (8, 18, 22).
Despite showing variable clinical performance, the GM-
ELISA is included in the revised European Organization for
Research and Treatment of Cancer (EORTC)/Mycoses Study
Group guidelines for defining invasive fungal disease (IFD) on
the basis of multicenter performance evaluation of a standard-
ized commercial method, whereas PCR is currently excluded
through a lack of standardization (4, 17).
Only recently has it become possible to purchase commer-
cial Aspergillus PCR assays, and the range of available products
remains severely limited compared to the in-house methods.
The fact that these in-house protocols have been in use for
almost 2 decades but have yet to gain widespread acceptance is
a direct consequence of a lack of standardization and multi-
center evaluation. The availability of a commercial PCR pro-
vides standardized methodology and improved stringency with
regard to all aspects of quality control and manufacture and is
a step toward incorporating PCR into diagnostic guidelines
(5). Multicenter evaluation of clinical performance is essential
and can be achieved by independent testing by individual cen-
ters, as was the case for GM-ELISA.
Aspergillus PCR has been used to test a variety of specimens
(bronchoalveolar lavage [BAL] fluid/sputum, serum/plasma,
whole blood, and tissue) with various degrees of success, al-
though direct comparison of specimen type and performance is
limited (22). Performance aside, the specimen choice may be
directly influenced by the patient’s condition, with invasive
specimens (BAL fluid, tissue) infrequently being taken. Addition-
ally, the requirements of a screening regime suited to the low
incidence of IA necessitate a high frequency of sampling (two to
three times/week). Testing of blood samples allows screening
regimes to be implemented, and neutropenic care pathways uti-
lizing PCR and ELISA have been shown to have utility in diag-
nosing and excluding IA (1). A definitive answer as to whether
whole blood or serum/plasma is the optimal specimen is yet to be
agreed to, although it is accepted that the use of serum is far less
technically demanding, targeting free circulating DNA (21, 22).
Commercial DNA extraction kits can be utilized, saving both time
and labor, and have the added benefit of providing further stan-
dardization, factors that are beneficial if Aspergillus PCR is to
attain widespread use as a diagnostic test.
In this study, the commercially available MycAssay Aspergillus
PCR (MAP; Myconostica Ltd., Manchester, United Kingdom)
was combined with the Roche High Pure Template DNA extrac-
tion kit (Roche, Burgess Hill, United Kingdom) so that it could be
used to test serum specimens for the presence of Aspergillus
DNA. Its analytical and clinical performance was compared to
that of a well-validated in-house Aspergillus PCR test (21, 23).
MATERIALS AND METHODS
In reporting this research, the Minimum Information for Publication of Quan-
titative Real-Time PCR Experiments (MIQE) guidelines have been incorpo-
rated, when appropriate, into a qualitative PCR assay (2).
* Corresponding author. Mailing address: Public Health Wales, Mi-
crobiology Cardiff, University Hospital of Wales, Heath Park, Cardiff
CF14 4XN, United Kingdom. Phone: 44 0 29 2074 6581. Fax: 44 0 29
2074 2161. E-mail: lewis.white@wales.nhs.uk.
 Published ahead of print on 30 March 2011.
† The authors have paid a fee to allow immediate free access to
this article.
2169
 o
n
 February 25, 2014 by Cardiff Univ
http://jcm.asm.org/
D
ow
nloaded from
 
DNA extraction from fungal cultures. Cultures of Aspergillus fumigatus ATCC
1022 were allowed to sporulate on Sabouraud agar plates before conidia were
harvested using a wet sterile loop. The conidia that adhered to the loop were
resuspended in sterile water containing a drop of Tween 20 (Sigma, United
Kingdom) to prevent clumping. The A. fumigatus suspension was serially diluted
to allow accurate quantification using a Fuchs Rosenthal hemocytometer. A
volume of suspension containing 106 conidia was pelleted by centrifugation
(10,000  g for 5 min), and the supernatant was discarded. The pellet was
exposed to mechanical disruption with the equivalent of 20 to 30 l of MagNA
Lyser Green beads (Roche, United Kingdom) and 30 s bead beating using a
minibeadbeater (Biospec Products). After pulse centrifugation, the beads were
washed with 200 l molecular-grade water and DNA was extracted using the
Roche High Pure Template DNA kit, per the manufacturer’s instructions, using
an elution volume of 65 l.
DNA extraction from serum specimens. As the Myconostica MycXtra kit is
specifically designed for testing BAL fluid specimens, DNA was extracted from
0.5 ml of serum using the Roche High Pure Template DNA kit. All reagents were
filter sterilized prior to use. To account for the larger input sample volume, initial
reagent volumes were doubled, resulting in a specimen mix requiring two appli-
cations to the spin column. Briefly, 0.5 ml of serum was mixed with 0.4 ml of
binding buffer and 80 l of recombinant proteinase K (Roche), and the mixture
was incubated at 70°C for 10 min. Two hundred microliters of isopropanol was
added and mixed by pipette before the entire specimen (by repeat addition) was
applied to the spin column by centrifugation at 8,000  g for 1 min. Other than
these modifications, the kit was used as per the manufacturer’s instructions, using
an elution volume of 65 l.
PCR. For all molecular assays, measures to control contamination and main-
tain performance were strictly followed (11). PCR efficiency was calculated using
the following equation: 1  10(1/slope) (2).
(i) IHP test. The in-house Aspergillus real-time PCR (IHP) test was per-
formed as a single-round assay using a Roche LightCycler (version 2.0) instru-
ment targeting the 28S rRNA gene as previously described, with 10 l DNA
input in a final reaction volume of 20 l (23). In addition to extraction controls,
PCR controls in the form of cloned PCR products (200, 20, and 2 input copies)
and no-template molecular-grade water were included to monitor PCR perfor-
mance. PCR positivity was determined using a threshold of 45 cycles.
(ii) IC PCR. The in-house internal control (IC) PCR targeted the capsular
transfer (ctrA) gene of Neisseria meningitidis. It was performed on the Roche
LightCycler (version 2.0) instrument, using the monoplex version of the assay, as
described by Corless et al. (3), using a 10-l DNA input in a final reaction volume
of 20 l (20). PCR controls in the form of the plasmid containing the ctrA gene
incorporated into the extraction procedure and no-template molecular-grade
water were included to monitor PCR performance.
(iii) MAP. MAP was performed on a Cepheid SmartCycler instrument as per
the manufacturer’s instructions using 10 l of DNA template in a final reaction
volume of 25 l and targeted the 18S rRNA gene. The kit contained positive and
no-template controls along with the master mix containing reagents for the
Aspergillus PCR and IC PCR, which was run as a duplex real-time PCR utilizing
fluorescently labeled beacons. PCR positivity was determined using a threshold
of 39 cycles.
Verification of analytical performance. To establish the detection range, limit
of detection, limit of blank, and reproducibility of the MAP assay when testing
serum, separate investigations were performed by the manufacturer and inde-
pendent testing center. Analytical specificity has been previously reported for
both Aspergillus PCR tests, and this will not change when testing a different
specimen type (6, 23). The analytical performance of the assays when testing
simulated serum specimens was determined prior to testing of clinical samples.
Detection range and LoD. A. fumigatus genomic DNA previously extracted
from known conidial quantities was diluted and used to spike serum samples with
various burdens before the DNA was extracted and the MAP assay was per-
formed. In addition, the independent center also tested the DNA extracts by the
IHP and IC PCR. Quantification was determined on the basis of one A. fumiga-
tus conidium containing one genome and the mean number of rRNA copies per
genome being 53 (9). Comparative evaluation of MAP and IHP performance in
detecting eight Aspergillus species (A. fumigatus, A. flavus, A. terreus, A. niger, A.
nidulans, A. versicolor, A. sclerotiorum, and A. glaucus) at a single burden was
determined. Reproducibility at the limit of detection (LoD) was determined by
the independent center for both assays by replicate testing during a single
experiment (n  5, intra-assay) and over multiple experiments (n  10, inter-
assay).
Determination of clinical performance. A pilot study was performed on a
group of 31 high-risk hematology patients. The study took the form of a retro-
spective anonymous service evaluation of hematology patients. As part of the
routine neutropenic fever care pathway, clotted blood specimens were sent twice
weekly for IA screening by PCR and GM-ELISA (1). After initial diagnostic
investigations, serum samples were stored at 80°C for future internal quality
assessment procedures and to permit service evaluation investigations. IFD was
defined according to the revised EORTC criteria (4). Ten cases were selected for
testing on the basis of having proven/probable IA, as defined by positive histo-
pathology and/or defined radiological signs plus GM-ELISA, and 21 patients
with no evidence of IA were used as a control population. The mean patient age
was 48.1 years, with an age range of 23 to 84 years. Of the 21 patients with no
evidence of IA, 7 were diagnosed with a respiratory virus infection and 3 with
cytomegalovirus infection, 1 had an Escherichia coli bacteremia, and 2 were
diagnosed with non-Aspergillus mold infections (1 with proven mucormycosis and
1 patient with Fusarium dimerum cultured from a respiratory specimen). The
remaining patients had no documented cause for their neutropenic fever.
For the purpose of this study, 0.5 ml of serum from patients with and without
IA was processed as described above. A total of 170 specimens (104 specimens
from 10 cases of proven/probable IA [median, 11; range, 4 to 22] and 66 from
patients at high risk of IA [median, 2; range, 1 to 22]) were retrospectively tested
by serum PCR.
DNA extracted from culture was serially diluted to obtain DNA concentra-
tions equivalent to ranges experienced in the clinical scenario (5 to 25 genome
equivalents [ge]) and added to serum for positive-control material. Negative
controls in the form of serum from a healthy donor were also used. To monitor
for sample inhibition and extraction efficiency, an IC was included in each
specimen.
RESULTS
Detection range. Both real-time assays were tested over a
5-log10 linear range of 5 to 5  10
4 ge per simulated serum
sample, which corresponds to 41 to  4  105 rRNA input
copies per PCR (Table 1 and Fig. 1). Both assays were able to
detect a range of Aspergillus species, although crossing point
(Cq) values were earlier for the MAP assay, and the IHP
detected A. glaucus only at a later stage of amplification (Table
2). When detecting 5,000 copies, the Cq value for the MycAs-
say Aspergillus was, on average, 5.95 cycles (range, 2.5 to 15.7
cycles) earlier than the Cq for the in-house PCR, and this was
more evident when testing DNA from non-A. fumigatus spe-
cies. One of 18 negative healthy donor serum samples, when
tested at the independent center, was positive by the IHP and
MAP assays on separate occasions. Retesting of these extracts
failed to confirm the false positivity, indicating that operator-
associated PCR setup contaminations were responsible for the
initial false positivity.
PCR efficiency, LoD, and reproducibility when testing se-
rum. The PCR efficiencies for the MAP and IHP assays were
calculated from the slope of each standard curve and were 1.01
and 0.90, respectively (Fig. 1). Cq values were earlier for the
MAP than the IHP (Table 1), although the assays used differ-
ent positivity thresholds. All extracts were easily detected
within the defined positivity ranges of the assays. The manu-
facturer’s 100% LoD for the MAP assay was 5 ge per sample
(16). For the independent center, an initial 100% LoD of 50 ge
per sample was determined for the MAP assay, with reproduc-
ibility for 5 ge being 80% (Table 1). This discrepancy was
attributed to the use of A. fumigatus genomic DNA that had
been subjected to long-term storage (6 months). Analysis of
results when using only freshly extracted DNA improved the
100% LoD for the MAP assay at the independent center to 5
ge per sample, generating a mean Cq value of 36.7 (standard
deviation [SD], 0.5; 95% confidence interval [CI], 36.2 to
37.1) cycles, confirming the manufacturer’s findings. The 100%
LoD for the IHP determined by the independent center was 50
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ge per sample, but again, removal of the data generated by the
testing of stored extracts improved this to 5 ge, generating a
mean Cq value of 38.3 (SD, 1.2; 95% CI, 37.1 to 39.4) cycles.
The interassay (between-run) mean Cq value for the MAP
assay at the LoD was 36.8 (n  10; SD, 0.6; 95% CI, 36.3 to
37.3) cycles. The intra-assay (within-run) mean Cq of the MAP
assay at the LoD was 36.4 (n  5; SD, 0.42; 95% CI, 35.9 to
36.9) cycles. The interassay mean Cq value for the IHP assay at
the LoD was 38.6 (n  10; SD, 1.4; 95% CI, 37.4 to 39.7)
cycles. The intra-assay mean Cq of the IHP assay at the LoD
was 37.9 (n  5; SD, 0.61; 95% CI, 37.1 to 38.6) cycles.
Determination of clinical performance. The diagnostic per-
formance parameters when testing 104 serum specimens from
10 patients with proven/probable IA and 66 serum specimens
from 21 patients at risk from IA by both real-time PCR assays
are shown in Table 3. Seven of the 10 patients with proven/
probable IA were MAP assay positive on at least one occasion,
and 6 had multiple (2) MAP-positive results. Eight of the
patients with proven/probable IA were IHP assay positive on at
least one occasion, and five had multiple (2) IHP-positive
results. Twenty of the 104 specimens from patients with prov-
en/probable IA were PCR positive when tested by the MAP
and IHP assays, with 13 MAP-positive and 12 IHP PCR-pos-
itive results being generated when testing samples taken within
1 week of clinical diagnosis and 71.4% and 75% of patients
with IA being MAP and IHP PCR positive, respectively, prior
to clinical signs.
Both assays are highly specific, with specificity values always
being 90%, and patients with multiple positive PCR results
were always associated with disease, as indicated by the likeli-
hood ratio positive (Table 3). The diagnostic odds ratios were
typical of those of Aspergillus PCR assays used to test blood
TABLE 1. Serum PCR positivity when testing simulated serum specimens spiked with various genomic burdens
Fungal burden
(no. of ge/0.5 ml serum)
MycAssay Aspergillus PCRa In-house Aspergillus PCRa
Cq difference
(no. of cycles)% positivity Mean no. of Cqcycles (SD) % positivity
Mean no. of Cq
cycles (SD)
50,000 (nd  2) 100 24.1 (0.1) 100 24.4 (0.2) 0.3
5,000 (n  3) 100 27.8 (0.5) 100 28.8 (1.3) 1.0
500 (n  4) 100 31.4 (0.3) 100 33.1 (0.6) 1.7
100 (n  3) 100 33.8 (1.6) 100 35.4 (1.5) 1.6
50 (n  3) 100 35.8 (0.5) 100 38.1 (0.8) 2.3
25 (n  24)b 91.6 35.8 (1.9) 95.2 37.3 (1.6) 1.5
25 (n  18)c 100 35.9 (2.1) 100 37.1 (1.7) 1.2
5 (n  10)b 80.0 36.8 (0.6) 80.0 38.6 (1.4) 1.7
5 (n  7)c 100 36.7 (0.5) 100 38.3 (1.2) 1.6
a Results of independent testing center.
b Data generated when testing fresh DNA and DNA template exposed to long-term storage.
c Data generated when testing fresh DNA template only.
d n, number of biological replicates tested at each burden. More replicates were tested at the lower burdens as, on the basis of published Cq values, these represent
clinically encountered burdens.
FIG. 1. Standard curve for the Myconostica MycAssay Aspergillus and in-house Aspergillus PCR assays when testing simulated serum
specimens. Data were plotted using mean Cq values and include those for all positive specimens. The box above the data points provides the linear
equation and the R2 (Pearson coefficient of determination) value for the in-house PCR assay. The box below the data points provides the linear
equation and R2 value for the MycAssay Aspergillus test.
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samples (13). A total of two samples from two separate pa-
tients at risk of IA generated false-positive results when tested
by the MAP assay. Inhibition rates were low for both serum
PCR assays, with 1.8% and 2.9% of all specimens deemed
inhibitory for the MAP and IHP assays, respectively. The mean
Cq values for positive samples from proven/probable IA pa-
tients were 37.1 and 38.9 cycles (difference, 1.8 cycles; 95% CI,
0.9 to 2.8 cycles; P  0.0002) for the MAP and IHP assays,
respectively.
Individual specimen concordance between serum PCR as-
says was good (Table 4). The accuracy between the two serum
PCR tests when testing serum from patients with proven/prob-
able IA was 88.5% (95% CI, 80.6 to 96.3%), generating a
kappa statistic of 0.63 (95% CI, 0.44 to 0.82). For the speci-
mens from patients without disease, the accuracy between the
two serum PCR tests was 97.0% (95% CI, 92.9 to 100%). The
overall accuracy between the two serum PCR tests was 91.8%
(95% CI, 86.5 to 97.0%), generating a kappa statistic of 0.62
(95% CI, 0.47 to 0.77), representing good agreement (Table 4).
DISCUSSION
An evaluation has been conducted to assess the performance
of a commercially available, and therefore standardized, Asper-
gillus PCR assay when testing serum. The performance of the
MycAssay Aspergillus assay was comparable to that of a well-
validated in-house PCR test, and both assays evaluated in this
study generated acceptable sensitivity values comparable to
previously published values for Aspergillus serum PCR assays
that generated pooled sensitivities of 72% (range, 53 to 100%;
95% CI, 66 to 77%) (22).
This was a retrospective serum PCR study; therefore, it is
relevant to consider the effects of storage and DNA degrada-
tion. When verifying the manufacturer’s LoD, initial testing of
stored DNA resulted in the reproducibility of detection being
reduced compared to that obtained by testing of freshly ex-
tracted DNA by values of 33.3% (95% CI, 3.9 to 70.0%) and
66.7% (95% CI, 6.5 to 93.9%) for burdens of 25 and 5 ge,
respectively. Many of the clinical specimens were stored for a
similar period (6 months), and it is therefore reasonable to
assume that some degradation will have occurred. As A. fu-
migatus DNA has been shown to be stable in serum and whole
blood for relatively short periods of time (144 h), it is likely
that a prospective study will improve detection rates (15).
Assay specificity was excellent, with all assays achieving
90% specificity irrespective of the definition of PCR positiv-
ity, indicating the importance of a single PCR-positive speci-
men, particularly when PCR positivity for blood samples may
be as low as 11% in patients with proven/probable IA (19).
However, in a previous review and meta-analysis of PCR used
to test blood specimens, a single PCR-positive result was as-
TABLE 2. Ability of PCR assays in detecting DNA extracted from
different Aspergillus speciesa
Species (no. of copies
input/reaction mixture) Strain identity
No. of cycles
MycAssay
Aspergillus
In-house
PCR
A. fumigatus (250-106) AF293 21.6–32.7 23.7–35.7
A. fumigatus (5,000) ATCC 13073 29.7 32.2
A. flavus (5,000) Clinical isolate 27.7 30.3
A. terreus (5,000) ATCC 20542 29.6 34.5
A. niger (5,000) ATCC 9029 31.1 36.0
A. nidulans (5,000) NEQAS 8226 29.1 33.5
A. versicolor (5,000) NEQAS 1581 31.0 36.2
A. sclerotiorum (5,000) Clinical isolate 27.0 34.4
A. glaucus (5,000) NEQAS 2/06 29.3 45.0
a The specificity panel was developed by the commercial partner using DNA
extracted from culture and donated to Myconostica by multiple independent
centers. DNA concentrations were measured and used to calculate numbers of
copies on the basis of 1 fg of genomic DNA containing 1 copy of the 18S rRNA
gene (10). Both PCR tests were performed in duplicate for each species. Five
thousand copies is equivalent to approximately 102 genomes (conidia), assuming
the mean number of rRNA genes of A. fumigatus to be 53 per genome (9). As the
number of copies of rRNA target will vary between Aspergillus species, the DNA
input has been provided as an approximate comparative guide and not for
quantitative purposes.
TABLE 3. Aspergillus serum PCR performance when testing clinical specimensa
Assay
No. of specimens
defining PCR
positivity
Sensitivity (%)b Specificity (%)b LR tive LR –tive DOR
MycAssay Aspergillus PCR Single 70.0 (39.7–89.2) 90.5 (71.1–97.4) 7.37 0.33 22.2
Multiple 60.0 (31.3–83.2) 100 (84.5–100)  (>60) 0.4 (0.4)  (>150)
In–house Aspergillus PCR Single 80.0 (49.0–94.3) 100 (84.5–100)  (>80) 0.2 (0.2)  (>400)
Multiple 50.0 (23.7–76.3) 100 (84.5–100)  (>50) 0.5 (0.5)  (>98.0)
a The patient population included 10 cases of proven/probable IA and 21 control patients with no evidence of IA. Values in boldface text are calculated using a
specificity of 99% in order to provide representative values as an interpretative guide to replace infinity. Abbreviations: Single, one specimen per patient was PCR
positive; Multiple, two or more specimens per patient were PCR positive; LR tive, likelihood ratio positive 	sensitivity/(1  specificity)
; LR –tive, likelihood ratio
negative 	(1  sensitivity)/specificity
; DOR, diagnostic odds ratio (number of specimens likelihood ratio positive/number of specimens likelihood ratio negative).
b 95% confidence intervals are given in parentheses.
TABLE 4. Concordance between serum specimens when tested by
the MycAssay Aspergillus and in-house Aspergillus PCR assays
In-house PCR
result
No. of specimensa
MycAssay Aspergillus
positive
MycAssay Aspergillus
negative
A B C A B C
Positive 14 14 0 6 6 0
Negative 8 6 2 142 78 64
a A, all samples (n  170); B, samples from cases of proven/probable IA (n 
104); C, samples from control patients with no IA (n  66).
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sociated with reduced specificity (13). In this study, PCR sam-
ple positivity when testing serum from patients with proven/
probable IA was higher (19.2%) but ranged from 0 to 100%
between individual patients, possibly representing sample deg-
radation. Low sample positivity rates may be a result of mini-
mal circulating target, and the mean Cq values for PCR-posi-
tive specimens provide mean fungal burdens of 11.6 and 10.1
ge/sample for the IHP and MAP assays, respectively. A low
circulating burden may be a consequence of testing blood
specimens to monitor for a disease that in its initial stages will
be focused in the respiratory tract, and for saprophytic diseases
(i.e., aspergilloma), assay sensitivity has been shown to be
compromised (24). Invasive disease progresses through tissue
and angioinvasion, providing a target in the bloodstream (fun-
gal cell-associated and free DNA [see below]) that may be
enhanced by the detection of conidia phagocytosed in alveolar
macrophages that have been translocated into the circulation,
a pathway that has been determined using macrophages con-
taining fluorescent particles (7). Nevertheless, as a true funge-
mia is unlikely with IA, the burden in blood will be low and
transient, requiring frequent screening to provide sensitivity.
A conclusive comparison of the performance of Aspergillus
PCR when testing serum/plasma or whole blood has yet to be
published. Technically, serum testing has many advantages
over whole-blood testing for Aspergillus PCR. Both PCR and
GM-ELISA can be performed on a single specimen, allowing
direct test comparison and providing cost and patient benefits.
Testing serum targets free circulating DNA, as any cell-asso-
ciated fungal DNA will be lost during the processing necessary
to fractionate the blood. In vivo release of DNA most likely
occurs through hyphal damage by autolysis or immune-medi-
ated damage. Many antifungal therapies target the fungal cell
wall or membrane, causing structural damage and DNA re-
lease, possibly enhancing detection (14). Targeting free circu-
lating DNA permits the use of simple commercial, possibly
automated, DNA extraction techniques, both standardizing
and improving turnaround time for Aspergillus PCR. The IC
target (usually plasmid DNA) is also more relevant for serum
than for whole blood, where it is likely to be destroyed or
decanted during the aggressive extraction procedure and can
be incorporated only in the later stages of the process. For
serum testing, this is not the case, and the incorporation of an
IC at the start of the extraction process monitors for both
inhibition and extraction efficiency on an individual sample
basis, eradicating the need for a positive extraction control,
thus removing a potential source of contamination. It must be
noted that currently the internal control for the MAP assay is
included in the PCR master mix and so can be used only to
monitor for PCR inhibition, as such a positive extraction con-
trol is required.
The retrospective performances of both serum PCR tests
highlight the importance of a prospective comparative study of
GM-ELISA, whole-blood Aspergillus PCR, and serum PCR in
order to determine an optimal specimen type and diagnostic
strategy. Although to provide a true comparison with GM-
ELISA it will be necessary to modify disease-defining criteria
or provide an evaluation of assay performance when testing
patients with histopathologically proven disease or cases of
probable IA defined by radiological evidence plus positive cul-
ture. Nevertheless, this retrospective evaluation of serum PCR
still generates performance statistics comparable to those of
GM-ELISA, which generated pooled sensitivities of 71% (95%
CI, 68 to 74%) and 78% (95% CI, 61 to 89%) (12, 17).
In conclusion, the aim of this study was to evaluate the
performance of an entirely commercially available Aspergillus
PCR assay providing a methodology that is standardized and
reagents that are quality controlled. The performance of the
MAP assay is comparable to that of an in-house PCR method
testing serum specimens and other previously evaluated com-
mercial tests (GM-ELISA) to aid in the diagnosis of IA. It is
essential that a large-scale evaluation of the MAP assay be
performed, and it is likely that a prospective evaluation will
improve clinical performance, as target degradation will be less
of a concern. By providing a standardized commercial ap-
proach, future multicenter performance parameters can be
determined without concerns regarding method variability,
permitting the clinical validity and utility of PCR to be accu-
rately determined at multiple independent sites.
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